A new Australian study has found that more than half of all reported adverse events involving medicinal cannabis products were linked to high-THC formulations, with psychiatric disorders — including anxiety, paranoia, and psychotic episodes — emerging as the most common harm. Researchers analysed over 1,100 adverse event reports submitted to the Therapeutic Goods Administration (TGA, Australia's medicines regulator) between mid-2022 and May 2025, covering products with THC concentrations ranging from 13% to over 88% — well above the 30–35% ceiling found in natural cannabis plants. The findings are particularly concerning because adverse events are widely believed to be under-reported, and the study identified 14 cases involving suicidal thoughts or attempts; researchers are calling for stricter prescribing oversight, especially for young people and those with existing mental health conditions.